Trial Radar
Sign in

NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Post Marketing Study on Pluvicto in Korea
Post Marketing Study on Pluvicto in Korea

NCT06514521

RecruitingN/A

Sponsor: Novartis Pharmaceuticals

Conditions: Metastatic Castration-resistant Prostate Cancer

Interventions: Lutetium vipivotide tetraxetan

Countries: South Korea

Post marketing study on Pluvicto in Korea

Eligibility overview

Sex: MALE

Age: 18 Years to 100 Years

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria
Inclusion criteria

Study participants eligible for inclusion in this study must meet all of the following criteria:

1. Male adult patient age ≥ 18
2. Subject who are being treated with Pluvicto or whose treatment plan is finalized and scheduled to be administered at the time of consent by physician in accordance with the approved indication in South Korea
3. Subject who provided the written informed consent prior to the study enrollment

Exclusion criteria

Study participants meeting any of the following criteria are not eligible for inclusion in this study:

1. Subject whose medical record is not accessible
2. Subject who is not willing to provide the informed consent
Locations (12)
  • Seongnam-si, Gyeonggi-do, South Korea
  • Suwon, Gyeonggi-do, South Korea
  • Busan, Korea, South Korea
  • Gyeonggi-do, Korea, South Korea
  • Seoul, Seoul, South Korea
  • Seoul, Seoul, South Korea
  • Jeollanam, South Korea
  • Seoul, South Korea
  • Seoul, South Korea
  • Seoul, South Korea
  • Seoul, South Korea
  • Seoul, South Korea